ZA202000157B - Antiproliferative compounds and methods of use thereof - Google Patents
Antiproliferative compounds and methods of use thereofInfo
- Publication number
- ZA202000157B ZA202000157B ZA2020/00157A ZA202000157A ZA202000157B ZA 202000157 B ZA202000157 B ZA 202000157B ZA 2020/00157 A ZA2020/00157 A ZA 2020/00157A ZA 202000157 A ZA202000157 A ZA 202000157A ZA 202000157 B ZA202000157 B ZA 202000157B
- Authority
- ZA
- South Africa
- Prior art keywords
- methods
- antiproliferative compounds
- antiproliferative
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762530778P | 2017-07-10 | 2017-07-10 | |
| US201762593185P | 2017-11-30 | 2017-11-30 | |
| US201862675581P | 2018-05-23 | 2018-05-23 | |
| PCT/US2018/041230 WO2019014100A1 (en) | 2017-07-10 | 2018-07-09 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202000157B true ZA202000157B (en) | 2021-08-25 |
Family
ID=63036419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/00157A ZA202000157B (en) | 2017-07-10 | 2020-01-09 | Antiproliferative compounds and methods of use thereof |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US10357489B2 (enExample) |
| EP (2) | EP4467143A3 (enExample) |
| JP (1) | JP7258009B2 (enExample) |
| KR (1) | KR102656934B1 (enExample) |
| CN (1) | CN110869021B (enExample) |
| AU (2) | AU2018301335B2 (enExample) |
| CA (1) | CA3069138A1 (enExample) |
| CL (1) | CL2020000060A1 (enExample) |
| CO (1) | CO2020000193A2 (enExample) |
| DK (1) | DK3651766T3 (enExample) |
| EC (1) | ECSP20001149A (enExample) |
| ES (1) | ES2992913T3 (enExample) |
| FI (1) | FI3651766T3 (enExample) |
| HR (1) | HRP20241553T1 (enExample) |
| HU (1) | HUE069137T2 (enExample) |
| IL (1) | IL271889B2 (enExample) |
| LT (1) | LT3651766T (enExample) |
| MX (1) | MX2023000085A (enExample) |
| PL (1) | PL3651766T3 (enExample) |
| PT (1) | PT3651766T (enExample) |
| RS (1) | RS66162B1 (enExample) |
| SA (1) | SA520411007B1 (enExample) |
| SG (1) | SG11202000143PA (enExample) |
| SI (1) | SI3651766T1 (enExample) |
| SM (1) | SMT202400470T1 (enExample) |
| TW (2) | TWI830576B (enExample) |
| WO (1) | WO2019014100A1 (enExample) |
| ZA (1) | ZA202000157B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10357489B2 (en) * | 2017-07-10 | 2019-07-23 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| KR20210018199A (ko) | 2018-03-26 | 2021-02-17 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스의 분해를 위한 세레블론 결합제 |
| EP4272737A3 (en) | 2018-04-23 | 2024-01-17 | Celgene Corporation | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma |
| CN113713095B (zh) * | 2018-05-23 | 2025-07-15 | 细胞基因公司 | 用于组合使用的抗增殖化合物和针对bcma和cd3的双特异性抗体 |
| US10969381B2 (en) | 2018-05-23 | 2021-04-06 | Celgene Corporation | Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile |
| MX2021005366A (es) | 2018-11-08 | 2021-09-10 | Juno Therapeutics Inc | Metodos y combinaciones para el tratamiento y modulacion de celulas t. |
| FI3908281T3 (fi) * | 2019-01-09 | 2024-10-01 | Celgene Corp | Antiproliferatiivisia yhdisteitä ja toisia aktiivisia aineita käytettäväksi multippelin myelooman hoidossa |
| CN118324742A (zh) * | 2019-01-09 | 2024-07-12 | 细胞基因公司 | 包含氧代异吲哚化合物及其盐的固体形式,以及包含它们的组合物和它们的使用方法 |
| US11779580B2 (en) * | 2019-01-09 | 2023-10-10 | Celgene Corporation | Pharmaceutical compositions comprising (s)-4-(4-(4- (((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrtle and methods of using the |
| KR20210152515A (ko) | 2019-04-12 | 2021-12-15 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| AR119715A1 (es) | 2019-04-12 | 2022-01-05 | Celgene Corp | Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona |
| WO2021080935A1 (en) | 2019-10-21 | 2021-04-29 | Celgene Corporation | Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benz yl)amino)isoindoline-1,3-dione |
| US20230065745A1 (en) | 2019-11-27 | 2023-03-02 | Captor Therapeutics S.A. | Piperidine-2,6-dione derivatives which bind to cereblon, and methods of use thereof |
| AU2020392427B2 (en) | 2019-11-27 | 2024-03-07 | Captor Therapeutics S.A. | Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof |
| JP7408819B2 (ja) | 2020-01-20 | 2024-01-05 | カング バイオファーマシューティカルズ リミテッド | イソインドリン誘導体、並びにその医薬組成物及び使用 |
| IL297139A (en) * | 2020-04-17 | 2022-12-01 | Escient Pharmaceuticals Inc | Modulators of mas-related g-protein receptor x4 and related products and methods |
| EP4142723A2 (en) * | 2020-04-28 | 2023-03-08 | Juno Therapeutics, Inc. | Combination of bcma-directed t cell therapy and an immunomodulatory compound |
| JP2023524068A (ja) * | 2020-04-30 | 2023-06-08 | ブリストル－マイヤーズ スクイブ カンパニー | サイトカイン関連有害事象を治療する方法 |
| JP2023531512A (ja) | 2020-06-25 | 2023-07-24 | セルジーン コーポレーション | 併用療法を用いて癌を治療するための方法 |
| CN113896711A (zh) * | 2020-07-06 | 2022-01-07 | 北京诺诚健华医药科技有限公司 | 杂环类免疫调节剂 |
| DK4178548T3 (da) * | 2020-07-07 | 2024-08-19 | Celgene Corp | Farmaceutiske sammensætninger omfattende (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUORBENZONITRIL |
| AU2021314401A1 (en) * | 2020-07-20 | 2023-03-09 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Sulfur-containing isoindoline derivative, and preparation method therefor and medical use thereof |
| BR112023001956A2 (pt) | 2020-08-03 | 2023-02-28 | Captor Therapeutics S A | Composto de fórmula (ia), (ib), (ic) ou (ii), composição farmacêutica, composto para uso ou composição farmacêutica para uso em um método de tratamento de câncer |
| WO2022146151A1 (en) | 2020-12-30 | 2022-07-07 | Captor Therapeutics S.A. | Novel compounds which bind to cereblon, and methods of use thereof |
| CN114685429A (zh) * | 2020-12-31 | 2022-07-01 | 江苏恒瑞医药股份有限公司 | 碳链环己二酰亚胺类化合物、其制备方法及其在医药上的应用 |
| WO2022152821A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| EP4347037A1 (en) * | 2021-05-27 | 2024-04-10 | Celgene Corporation | Methods of treating multiple myeloma using combination therapy |
| WO2022255890A1 (en) | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Compounds which bind to cereblon, and use thereof |
| WO2022255889A1 (en) | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Compounds which bind to cereblon, and use thereof |
| CA3223636A1 (en) | 2021-08-06 | 2023-02-09 | Christopher Walton CARROLL | Compositions and methods for selective degradation of engineered proteins |
| CN116023319A (zh) * | 2021-10-25 | 2023-04-28 | 英格尔医药科技(上海)有限公司 | 制备布瓦西坦的方法 |
| CA3248757A1 (en) * | 2022-01-19 | 2025-07-09 | Jiangsu Hengrui Pharmaceuticals Co Ltd | CRYSTALLINE FORM OF A SULFUR-CONTAINING ISOINDOLINE DERIVATIVE |
| WO2024167423A1 (en) | 2023-02-07 | 2024-08-15 | Captor Therapeutics S.A. | Gspt1 degrader compounds |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0011313A1 (en) | 1977-07-09 | 1980-05-28 | LUCAS INDUSTRIES public limited company | Road vehicle electrical systems |
| DE2848746A1 (de) | 1978-11-10 | 1980-05-22 | Wolfgang Arheiliger | Dichtung fuer eine schwellenlose tuere mit drehfluegel |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| WO2000034437A2 (en) | 1998-12-08 | 2000-06-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| US20060074103A1 (en) | 2004-10-06 | 2006-04-06 | Corte James R | Cyclic beta-amino acid derivatives as factor Xa inhibitors |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| GB0514018D0 (en) | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
| RU2396265C2 (ru) | 2006-02-17 | 2010-08-10 | Ф. Хоффманн-Ля Рош Аг | Производные бензоилпиперидина в качестве модуляторов рецепторов 5ht2 и d3 |
| WO2008091670A2 (en) | 2007-01-24 | 2008-07-31 | Polyera Corporation | Organic semiconductor materials and precursors thereof |
| EP2142534B1 (en) | 2007-03-20 | 2016-08-10 | Celgene Corporation | 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| ES2592216T3 (es) | 2008-09-26 | 2016-11-28 | Dana-Farber Cancer Institute, Inc. | Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos |
| US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
| WO2010057087A1 (en) | 2008-11-17 | 2010-05-20 | Plextronics, Inc. | Organic photovoltaic devices comprising substituted endohedral metallofullerenes |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| CA2744563A1 (en) | 2008-12-12 | 2010-06-17 | Ariad Pharmaceuticals, Inc. | Azaindole derivatives as kinase inhibitors |
| US8741295B2 (en) | 2009-02-09 | 2014-06-03 | Universite De La Mediterranee | PD-1 antibodies and PD-L1 antibodies and uses thereof |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| SG10201501062SA (en) * | 2010-02-11 | 2015-04-29 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| WO2011146401A1 (en) | 2010-05-17 | 2011-11-24 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| ES2612503T3 (es) | 2010-09-14 | 2017-05-17 | Exelixis, Inc. | Compuestos 9H-purina como inhibidores de PI3K-delta y métodos para su preparación |
| JP5728921B2 (ja) | 2010-12-10 | 2015-06-03 | コニカミノルタ株式会社 | 光学フィルム、及びそれを用いた偏光板、液晶表示装置 |
| WO2012080729A2 (en) | 2010-12-14 | 2012-06-21 | Electrophoretics Limited | CASEIN KINASE 1δ (CK1δ) INHIBITORS |
| AU2012236655B2 (en) | 2011-03-28 | 2016-09-22 | Deuterx, Llc, | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| WO2012138734A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| TW201408652A (zh) | 2012-07-11 | 2014-03-01 | Hoffmann La Roche | 作爲ＲＯＲｃ調節劑之芳基磺內醯胺衍生物 |
| EP2882442B1 (en) | 2012-08-09 | 2021-06-09 | Celgene Corporation | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| US9682952B2 (en) | 2012-09-04 | 2017-06-20 | Celgene Corporation | Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl) piperidine-2-6-dione and methods of preparation thereof |
| WO2014116573A1 (en) | 2013-01-22 | 2014-07-31 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| CN113244205A (zh) | 2013-08-22 | 2021-08-13 | 万达制药公司 | 多发性骨髓瘤的治疗 |
| WO2016012965A2 (en) | 2014-07-25 | 2016-01-28 | Piramal Enterprises Limited | Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof |
| WO2016019386A1 (en) | 2014-08-01 | 2016-02-04 | Green Revolution Cooling, Inc. | Controller for oil-cooled rack with multiple modes of operation |
| EP3310169B1 (en) | 2015-05-30 | 2023-05-17 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| HK1250235A1 (zh) | 2015-07-08 | 2018-12-07 | F. Hoffmann-La Roche Ag | 作为rorc调节剂的芳基磺内酰胺衍生物 |
| EP3429591B1 (en) | 2016-03-16 | 2023-03-15 | Kura Oncology, Inc. | Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use |
| KR102387316B1 (ko) | 2016-04-06 | 2022-04-15 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Mdm2 단백질 분해제 |
| US20190054097A1 (en) | 2016-04-21 | 2019-02-21 | Bioventures, Llc | Compositions targeting senescent cells and the uses thereof |
| KR102447884B1 (ko) | 2016-04-21 | 2022-09-27 | 바이오벤처스, 엘엘씨 | 항-세포자멸적 bcl-2 계열 단백질의 열화를 유도하는 화합물 및 이의 용도 |
| CN109642048A (zh) | 2016-08-30 | 2019-04-16 | 陶氏环球技术有限责任公司 | 减小丙烯醛浓度的方法 |
| AU2017343565A1 (en) | 2016-10-10 | 2019-05-30 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepine (IQB)-1(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimers |
| HUE070289T2 (hu) | 2016-10-11 | 2025-05-28 | Arvinas Operations Inc | Vegyületek és módszerek az androgénreceptor célzott lebontására |
| ES2916335T3 (es) | 2016-10-20 | 2022-06-30 | Celgene Corp | Receptores de antígeno quimérico heterodimerizable basados en cereblon |
| CA3045037A1 (en) | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
| EP3577109A4 (en) | 2017-01-31 | 2020-11-18 | Arvinas Operations, Inc. | CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM |
| US10357489B2 (en) * | 2017-07-10 | 2019-07-23 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| US10513515B2 (en) | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
| JP7565078B2 (ja) | 2017-12-13 | 2024-10-10 | 上海科技大学 | Ａｌｋタンパク質分解剤及びそれらの癌療法における使用 |
| CN113713095B (zh) * | 2018-05-23 | 2025-07-15 | 细胞基因公司 | 用于组合使用的抗增殖化合物和针对bcma和cd3的双特异性抗体 |
| CN108690020A (zh) | 2018-07-04 | 2018-10-23 | 清华大学 | 一种靶向降解bet蛋白的化合物及其应用 |
| CN108794453A (zh) | 2018-07-05 | 2018-11-13 | 清华大学 | 一种靶向降解fak蛋白的化合物及其应用 |
-
2018
- 2018-07-09 US US16/030,695 patent/US10357489B2/en active Active
- 2018-07-09 CN CN201880045745.6A patent/CN110869021B/zh active Active
- 2018-07-09 SI SI201831174T patent/SI3651766T1/sl unknown
- 2018-07-09 TW TW112101268A patent/TWI830576B/zh active
- 2018-07-09 ES ES18746444T patent/ES2992913T3/es active Active
- 2018-07-09 KR KR1020207003734A patent/KR102656934B1/ko active Active
- 2018-07-09 HU HUE18746444A patent/HUE069137T2/hu unknown
- 2018-07-09 SM SM20240470T patent/SMT202400470T1/it unknown
- 2018-07-09 PL PL18746444.1T patent/PL3651766T3/pl unknown
- 2018-07-09 RS RS20241263A patent/RS66162B1/sr unknown
- 2018-07-09 JP JP2020500862A patent/JP7258009B2/ja active Active
- 2018-07-09 DK DK18746444.1T patent/DK3651766T3/da active
- 2018-07-09 CA CA3069138A patent/CA3069138A1/en active Pending
- 2018-07-09 LT LTEPPCT/US2018/041230T patent/LT3651766T/lt unknown
- 2018-07-09 FI FIEP18746444.1T patent/FI3651766T3/fi active
- 2018-07-09 PT PT187464441T patent/PT3651766T/pt unknown
- 2018-07-09 WO PCT/US2018/041230 patent/WO2019014100A1/en not_active Ceased
- 2018-07-09 IL IL271889A patent/IL271889B2/en unknown
- 2018-07-09 HR HRP20241553TT patent/HRP20241553T1/hr unknown
- 2018-07-09 AU AU2018301335A patent/AU2018301335B2/en active Active
- 2018-07-09 EP EP24192984.3A patent/EP4467143A3/en active Pending
- 2018-07-09 SG SG11202000143PA patent/SG11202000143PA/en unknown
- 2018-07-09 EP EP18746444.1A patent/EP3651766B1/en active Active
- 2018-07-09 TW TW107123698A patent/TWI791552B/zh active
-
2019
- 2019-06-03 US US16/430,189 patent/US10675281B2/en active Active
-
2020
- 2020-01-08 SA SA520411007A patent/SA520411007B1/ar unknown
- 2020-01-08 EC ECSENADI20201149A patent/ECSP20001149A/es unknown
- 2020-01-09 CL CL2020000060A patent/CL2020000060A1/es unknown
- 2020-01-09 ZA ZA2020/00157A patent/ZA202000157B/en unknown
- 2020-01-09 CO CONC2020/0000193A patent/CO2020000193A2/es unknown
- 2020-01-10 MX MX2023000085A patent/MX2023000085A/es unknown
- 2020-04-27 US US16/859,357 patent/US11185543B2/en active Active
-
2021
- 2021-11-08 US US17/521,432 patent/US12029738B2/en active Active
-
2022
- 2022-12-13 AU AU2022287569A patent/AU2022287569B2/en active Active
-
2024
- 2024-01-23 US US18/419,894 patent/US20240207255A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202000157B (en) | Antiproliferative compounds and methods of use thereof | |
| IL276946A (en) | Antiproliferative compounds and methods of use | |
| ZA201905677B (en) | Glycan-interacting compounds and methods of use | |
| IL273236A (en) | Pyrazolopyrimidine compounds and their uses | |
| PL3548033T3 (pl) | Związki i sposoby ich stosowania | |
| GB201617508D0 (en) | Use of Barocaloric materials and Barocaloric devices | |
| IL292488B1 (en) | Pyridineamine-pyridone and pyrimidineamine-pyridone compounds | |
| IL283387A (en) | Diarylhydantoin compounds and methods of use thereof | |
| GB201609786D0 (en) | Compounds and method of use | |
| IL269836B (en) | Converted N-arylethyl-2-aminoquinoline-4-carboxamides and their use | |
| IL265531A (en) | N 3 -cyclically substituted thienouraciles and use thereof | |
| IL292482B1 (en) | Azaindolylpyridone and diazaindolylpyridone compounds | |
| IL267937A (en) | Amide compounds and their use | |
| GB201700404D0 (en) | Compounds and composistions | |
| IL269843B (en) | Converted N-arylethyl-2-arylquinoline-4-carboxamides and their use | |
| IL265617B (en) | 1-phenylpropanone compounds and their use | |
| GB201719043D0 (en) | Methods and compounds | |
| GB201720943D0 (en) | New processes and compounds | |
| GB201712049D0 (en) | Novel compounds and their use |